What was the primary outcome of the ARISTOTLE trial?
The primary outcome of the ARISTOTLE trial was the occurrence of stroke or systemic embolism over a median 1.8 years of follow-up in the apixaban group (analyzed as intention to treat) and 1.60%/y in the warfarin group (HR, 0.79; 95% CI, 0.66–0.95; P=0.01 for superiority).